PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27684575-0	2017	Anti-tumor efficacy study of the Bruton"s tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.	Nitrogen Dioxide	75-78	Bruton tyrosine kinase	Homo sapiens	59-62	
29690649-0	2018	Responses to the Selective Bruton"s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.	Nitrogen Dioxide	82-85	Bruton tyrosine kinase	Homo sapiens	27-51	
31087308-2	2019	Patients with X-linked agammaglobulinemia due to hereditary Btk deficiency do not show bleeding, but a mild bleeding tendency is observed in high dose therapy of B-cell malignancies with ibrutinib and novel second-generation irreversible Btk inhibitors (acalabrutinib and ONO/GS-4059).	Nitrogen Dioxide	272-275	Bruton tyrosine kinase	Homo sapiens	60-63	
29559479-3	2018	We found that ibrutinib and the novel Btk inhibitors acalabrutinib and ONO/GS-4059 block GPVI-dependent static platelet aggregation in blood exposed to human plaque homogenate and collagen but not to ADP or arachidonic acid.	Nitrogen Dioxide	71-74	Bruton tyrosine kinase	Homo sapiens	38-41	
27684575-3	2017	Given the high potency and selectivity of the BTK inhibitor, ONO/GS-4059, it was hypothesized that, the anti-tumor activity of ONO/GS-4059 could be further enhanced by combining it with the anti-CD20 Abs, rituximab (RTX) or obinutuzumab (GA101).	Nitrogen Dioxide	61-64	Bruton tyrosine kinase	Homo sapiens	46-49	
27684575-3	2017	Given the high potency and selectivity of the BTK inhibitor, ONO/GS-4059, it was hypothesized that, the anti-tumor activity of ONO/GS-4059 could be further enhanced by combining it with the anti-CD20 Abs, rituximab (RTX) or obinutuzumab (GA101).	Nitrogen Dioxide	127-130	Bruton tyrosine kinase	Homo sapiens	46-49	
28178345-0	2017	PI3Kdelta inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kdelta and BTK inhibitors.	Nitrogen Dioxide	65-68	Bruton tyrosine kinase	Homo sapiens	51-54	
27776353-0	2017	Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.	Nitrogen Dioxide	33-36	Bruton tyrosine kinase	Homo sapiens	0-22	
26542378-0	2016	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.	Nitrogen Dioxide	56-59	Bruton tyrosine kinase	Homo sapiens	42-45	
26542378-1	2016	We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies.	Nitrogen Dioxide	125-128	Bruton tyrosine kinase	Homo sapiens	86-108	
26542378-1	2016	We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies.	Nitrogen Dioxide	125-128	Bruton tyrosine kinase	Homo sapiens	110-113